2021
DOI: 10.3390/ijms22052440
|View full text |Cite
|
Sign up to set email alerts
|

Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography

Abstract: The need for remyelinating drugs is essential for healing disabling diseases such as multiple sclerosis (MS). One of the reasons for the lack of this class of therapies is the impossibility to monitor remyelination in vivo, which is of utmost importance to perform effective clinical trials. Here, we show how optical coherence tomography (OCT), a cheap and non-invasive technique commonly used in ophthalmology, may be used to assess remyelination in vivo in MS patients. Our pioneer approach validates OCT as a te… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(8 citation statements)
references
References 78 publications
(106 reference statements)
0
8
0
Order By: Relevance
“…[38][39][40] Regarding the observed effect in EAE, our current results were relatively stronger than those obtained in other studies. 33,50,51 Despite the effects directly obtained in OPCs in vitro, LRRK2 inhibition with compound 4 may reflect the anti-inflammatory effect that is previously known from different scenarios and very recently suggested in patients with Parkinson's disease, too. 52,53 It is known that OPCs are especially vulnerable to inflammation at the peak of the disease.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[38][39][40] Regarding the observed effect in EAE, our current results were relatively stronger than those obtained in other studies. 33,50,51 Despite the effects directly obtained in OPCs in vitro, LRRK2 inhibition with compound 4 may reflect the anti-inflammatory effect that is previously known from different scenarios and very recently suggested in patients with Parkinson's disease, too. 52,53 It is known that OPCs are especially vulnerable to inflammation at the peak of the disease.…”
Section: Discussionmentioning
confidence: 99%
“…Treatments available for RR‐MS to date have failed to positively impact on the progressive phases of MS, 56‐58 which points to the need of future approaches combining different classes of compounds for both the RR‐MS and the progressive phases of MS (SP‐MS, PP‐MS). Although we cannot discard that compound 4 would cover both physiopathological aspects by itself, as in other compounds, 33,55 the incorporation of LRRK2 inhibitors into the MS therapeutic arsenal will open horizons for effective combinations with currently available immunomodulators. In addition, the simple chemical structure and synthesis of compound 4 opens the possibility of further structural modification to tailor its effects.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, one of these derivatives (VP3.15) was tested in in vivo studies in models of retinitis pigmentosa, autoimmune encephalomyelitis (AE), and multiple sclerosis (MS) [ 89 , 90 ]. VP3.15 exerted neuroprotective, anti-inflammatory, and remyelinating effects in an MS mouse model [ 91 ], suggesting its potential as a disease-modifying drug for MS treatment. In addition to this promising pharmacological application, VP3.15 is the first dual GSK-3 cAMP phosphodiesterase 7 (PDE7) inhibitor ever reported [ 92 ].…”
Section: Gsk-3β Inhibitionmentioning
confidence: 99%
“…2022, 23, 978 2 of 15 glycoprotein [5]. For instance, one of the clinical manifestations of MS is optic neuritis, which is an inflammatory optic neuropathy that can affect one or both ONs [6]. While some of these diseases are spontaneous and appear in later stages of life, others-such as hypomyelinating leukodystrophies-appear during infancy or early childhood, as they are associated with neurodevelopmental defects [7,8].…”
Section: Introductionmentioning
confidence: 99%